TORONTO and DALLAS, Feb. 25, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its common shares will begin trading on the OTCQX® Best Market under the symbol "PYNKF", effective with the open of business on February 27, 2025. "Many of our shareholders are based in the United States and the U.S. is the primary...Read more
Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A...Read more
San Diego, California--(Newsfile Corp. - February 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF. The...Read more
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, today announced the pricing of its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. All of the shares of...Read more
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting...Read more
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence trading on the OTCQB under symbol HMTXF today, January 23, 2025, while the Company presents "Welcome to Your Fountain of Youth!" at the Sequire Investor Summit at 11:00 a.m. "Listing on the OTCQB enables US investors to buy into their...Read more
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time...Read more
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’. The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing. Each ADS represents...Read more
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics’ shares are expected to begin trading on the Nasdaq...Read more
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross...Read more
CARMEL, Ind., September 9, 2024 (GLOBE NEWSWIRE) – MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the launch of its initial public offering of 8,500,000 shares of its common stock pursuant to a registration statement filed with the Securities and...Read more
Hangzhou, China, Aug. 26, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (the "Company"), a supplier of medical devices in China, today announced the closing of the initial public offering (the "Offering") of its 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares commenced trading on the Nasdaq Capital Market on August 23, 2024 under the ticker symbol...Read more
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross...Read more
ROCKVILLE, Md. & NEW YORK / Jul 31, 2024 / Business Wire / OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share, raising gross proceeds of $6.4 million. Additionally, the...Read more
BRENTWOOD, Tenn. / Jul 19, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (f/k/a Ardent Health Partners, LLC and collectively “Ardent Health” or the “Company”), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the closing of its initial public offering (the “Offering”) of 12,000,000 shares of its common stock sold by the Company at a public offering price of $16 per...Read more
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25 GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology MENLO PARK, Calif., June 24, 2024 — GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off from Illumina (NASDAQ: ILMN) is complete, and GRAIL will be listed and...Read more
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors. As the sole...Read more
SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering (IPO) on the Nasdaq stock exchange. This achievement marks MNDR as the first pure-play telehealth company from APAC to list on a major US stock exchange. “This IPO is a significant achievement for MNDR and reflects the surging demand for...Read more
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global...Read more
Company's Listing Application Approved by Nasdaq VICTORIA, BC, April 3, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq...Read more
Auna’s mission is to transform healthcare in Latin America, providing access to a highly integrated offering of quality healthcare services in Spanish-speaking Americas. Auna has built one of Latin America´s largest modern healthcare platforms, with presence in Mexico, Colombia and Peru. 2023 revenues of US$1.05 billion and Adjusted EBITDA of US$223 million, up 58% and 90%, respectively, with Adjusted EBITDA margin expanding to...Read more
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto. In...Read more
BEIJING, Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share...Read more
TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023. Medicenna’s shares will continue to trade on the Toronto Stock Exchange...Read more
BEIJING, Nov. 13, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that its subsidiary Miracle Laser Systems, Inc. ("Wuhan Miracle") recently has submitted the application documents for its potential initial public offering ("IPO") and...Read more
SAN MATEO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the pricing of its initial public offering of 18,750,000 shares of its common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by CARGO. The gross...Read more
VANCOUVER, British Columbia, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access segment of the AQSE...Read more
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has qualified for trading on the OTCQB Venture Market (the "OTCQB") in the United States operated by the OTC Markets Group Inc. and...Read more
BEVERLY, Mass. and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced its graduation from the TSX Venture Exchange to the Toronto Stock Exchange (TSX) main board, effective September 7, 2023. Hamilton Thorne’s symbol (HTL) will...Read more
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”) (NYSE American: RHE) (NYSE American: RHE-PA) (OTCQB Venture: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that its 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) commenced trading on...Read more
TORONTO, June 7, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (Frankfurt: 8TV) (OTC: AINMF), is pleased to announce that after a successful application process the Company's common shares will begin trading on the OTCBQ® Market (the "OTCQB") at the opening of the market on June 7, 2023, under the stock symbol "AINMF". The Company believes that the move to the OTCQB will provide enhanced investor...Read more
Leading biotech/biopharm company MindBio lists on the Canadian Securities Exchange Psychedelic medicine fund, Negev Capital is a shareholder Successful completion of Phase 1 trial and two fully funded Phase 2 trials begin shortly World first take-home approvals for LSD-Microdosing clinical trials. VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (the "Company" or "MindBio") is pleased to...Read more
NEW BRUNSWICK, N.J. & SKILLMAN, N.J. / May 03, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to...Read more
NEW BRUNSWICK, N.J. / Apr 24, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its...Read more
SAN DIEGO / Mar 06, 2023 / Business Wire / Ambrx Biopharma Inc. (NYSE: AMAM) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker...Read more
EDEN PRAIRIE, MN, Jan. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (OTCQB: SNWV) (“SANUWAVE”), a leading provider of next-generation FDA-approved wound care products, is pleased to announce that its common stock commenced trading on the OTCQB today. About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological...Read more
PITTSBURGH, Dec. 22, 2022 /PRNewswire/ — Lipella Pharmaceuticals Inc. ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the closing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per...Read more
Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics, Inc. (“Yumanity”). The combined company will operate...Read more
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory...Read more
Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the “Company” or “LAX”) (NASDAQ: LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the “Business Combination”) with EUDA Health Ltd (“EUDA Health”), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient...Read more
Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity (“PIPE”), led by Frazier Healthcare Partners and Bain Capital Life Sciences Gross proceeds from the transactions...Read more
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023MAA validated in the European Union Under Review SAN DIEGO – November 8, 2022 – ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) (ARS or the Company), a biopharmaceutical company dedicated to...Read more
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif., November 01, 2022--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista Public Acquisition Corp. II...Read more
SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE